



## Advances in Oral Vaccine Development

Guest Editor:

**Dr. Shaun Pennington**

Liverpool School of Tropical  
Medicine, Liverpool, UK

Deadline for manuscript  
submissions:

**31 August 2024**

### Message from the Guest Editor

Most human pathogens invade via a mucosal site. Through oral vaccination, it is possible to generate protective immune responses tailored towards mucosal immune defence. Practical considerations make oral vaccines ideal for paediatric administration, as well as for integration into mass administration programmes.

The use of trivalent and bivalent oral polio vaccines led to the eradication of wild poliovirus type 2 in 2015 and wild poliovirus type 2 in 2019. These successes highlight the potential impact of oral vaccination programmes, and we feel that research should be supported towards the development of novel oral vaccines targeting bacterial and viral pathogens.

With this in mind, we invite researchers with new knowledge of relevance to the field of oral vaccine development to submit to this Special Issue, entitled “Advances in Oral Vaccine Development”. There are no limitations on the paper type; original research articles, reviews, or short communications are warmly welcome.





an Open Access Journal by MDPI

## Editor-in-Chief

### **Prof. Dr. Ralph A. Tripp**

Department of Infectious  
Diseases, College of Veterinary  
Medicine, University of Georgia,  
Athens, GA 30602-7387, USA

## Message from the Editor-in-Chief

*Vaccines* (ISSN 2076-393X) has had a 6-year history of publishing peer-reviewed state of the art research that advances the knowledge of immunology in human disease protection. Immunotherapeutics, prophylactic vaccines, immunomodulators, adjuvants and the global differences in regulatory affairs are some of the highlights of the research published that have shaped global health. Our open access policy allows all researchers and interested parties to immediately scrutinize the rigorous evidence our publications have to offer. We are proud to present the work and perspectives of many to contribute to future decisions concerning human health.

## Author Benefits

**Open Access:** free for readers, with **article processing charges (APC)** paid by authors or their institutions.

**High Visibility:** indexed within **Scopus**, **SCIE (Web of Science)**, **PubMed**, **PMC**, **Embase**, **CAPLus / SciFinder**, and **other databases**.

**Journal Rank:** JCR - Q1 (*Immunology*) / CiteScore - Q1 (*Pharmacology (medical)*)

## Contact Us

---

*Vaccines* Editorial Office  
MDPI, St. Alban-Anlage 66  
4052 Basel, Switzerland

Tel: +41 61 683 77 34  
[www.mdpi.com](http://www.mdpi.com)

[mdpi.com/journal/vaccines](http://mdpi.com/journal/vaccines)  
[vaccines@mdpi.com](mailto:vaccines@mdpi.com)